2cureX AB establishes collaboration with Scandion Oncology A/S and Erasmus Medical Centre, Rotterdam, in drug-resistant breast cancer patients

June 16 | 2020

2cureX AB (“2cureX”) today announces that it together with Scandion Oncology A/S, Copenhagen and Erasmus Medical Centre, Rotterdam has received a grant of 800.000 EUR from Eurostars. The grant will be used to study if Scandion Oncology’s drug candidate, SCO -101 can overcome resistance to antiestrogen therapy in metastatic breast cancer patients, and if 2cureX’s IndiTreast test can stratify such patients based on SCO-101 sensitivity.

Breast cancer is the most common cancer in women with more than 560.000 new cases in Europe every year. 15-20% of breast cancer patients will experience cancer spread to other organs, so called metastatic disease. Women suffering from metastatic breast cancer are often treated with antiestrogens. Unfortunately, almost all these patients will at some point become resistant to the treatment. Preclinical data have shown that SCO-101 can reverse antiestrogen resistance. In the present project it will be evaluated whether SCO-101 also can circumvent such resistance in a clinical setting. 2cureX will use its IndiTreat test to identify those patients with the highest likelihood of obtaining benefit from SCO-101 treatment.

Nils Brünner, CEO of Scandion Oncology says: “In Scandion Oncology we see a tremendous potential for SCO-101 in helping women with metastatic breast cancer that do no longer respond to antiestrogen treatment. It is therefore a pleasure to have 2cureX “on-board” with their IndiTreat technology. IndiTreat will allow us to select the metastatic patients where SCO-101 can overcome resistance. Such selection will be essential in coming clinical trials and beyond”.

Ole Thastrup, CEO of 2cureX continues: “It is a pleasure for us to be involved in this project with an attractive biotech partner like Scandion Oncology and a new international clinical partner, Erasmus Medical Centre, Rotterdam. We are convinced that effective stratification of cancer patients during clinical trials and after market introduction will be critical in a large number of future drug development activities. Such stratification will limit the number of patients needed to be enrolled in clinical trials, lower costs and bring new drugs to patients faster.

In 2019 we signed our first stratification agreement with Gibson Oncology in which 2cureX will stratify metastatic colorectal cancer (mCRC) patients based on their sensitivity to the drug candidate LMP400. Now we want to transfer our knowledge from mCRC to metastatic breast cancer patients, where there is a large clinical need”.

For more information about 2cureX:
Ole Thastrup, Chief Executive Officer
E-mail: ot@2curex.com
Telephone: +45 22 11 53 99
www.2curex.com

Certified Adviser
Redeye AB
Telephone: +46 8 121 576 90
E-mail: certifiedadviser@redeye.se

This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on June 16th, 2020.

2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumors that are similar to the patient’s tumor and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.

IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.

IndiTreat® is presently being introduced into the European market through an Early Access Program.

The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.

The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).